Drugs that contain Methylphenidate Hydrochloride

1. Drug name - ADHANSIA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Nov, 2038

(16 years from now)

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
35MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
45MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
55MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
70MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
85MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

2. Drug name - JORNAY PM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder Mar, 2032

(9 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder Mar, 2032

(9 years from now)

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
40MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
60MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
80MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
100MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

3. Drug name - METHYLIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880 SPECGX LLC Methylphenidate solution and associated methods of administration and production Oct, 2024

(2 years from now)

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/5ML SOLUTION;ORAL Prescription
10MG/5ML SOLUTION;ORAL Prescription

4. Drug name - QUILLICHEW ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8202537 NEXTWAVE PHARMS Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

US8287903 NEXTWAVE PHARMS Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US9295642 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US9545399 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US11103495 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US10857143 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US11103494 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US8999386 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US9844544 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

Treatment: A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1; A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription

5. Drug name - QUILLIVANT XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 NEXTWAVE Modified release formulations containing drug-ion exchange resin complexes Mar, 2029

(6 years from now)

US8563033 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US9040083 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8465765 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8287903 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8778390 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

US8956649 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product Feb, 2031

(8 years from now)

Treatment: Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.